Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cell and Gene Therapy Global Market Opportunities And Strategies To 2035 Published — Analyzes Hospitals, Cancer Care Centers and Other End Users

globenewswire.com
GILD Gilead Sciences is a leading competitor in the cell and gene therapy market with a 15.3% market share, indicating strong positioning for future growth in this expanding sector. NVS Novartis AG holds a significant 12.8% market share in the cell and gene therapy market, positioning it well to benefit from the sector's projected substantial growth. BMY Bristol-Myers Squibb has an 8.9% market share in the cell and gene therapy market, suggesting a solid presence and potential to capitalize on the sector's growth. JNJ Johnson & Johnson holds a 7.5% market share in the cell and gene therapy market, indicating a significant player poised to benefit from the industry's expansion. SRPT Sarepta Therapeutics has a 6.4% market share in the cell and gene therapy market, positioning it to benefit from the strong growth projected for the sector. VRTX Vertex Pharmaceuticals holds a 6.1% market share in the cell and gene therapy market, indicating a strong position to capitalize on the sector's significant growth prospects. AMGN Amgen is listed as a prominent participant in the cell and gene therapy market, but the article does not provide specific details on its market share or growth contribution.

Cell and Gene Therapy Global Market Opportunities And Strategies To 2035 Published — Analyzes Hospitals, Cancer Care Centers and Other End Users Dublin, July 20, 2026 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Global Market Opportunities and Strategies to 2035" has been added to ResearchAndMarkets.com's offering.

The global cell and gene therapy market reached approximately $15.92 billion in 2025, following a compound annual growth rate (CAGR) of 23.4% from 2020. The market is projected to expand at a CAGR of 22.6% to reach $44.19 billion by 2030, before advancing at a CAGR of 21.1% to approximately $114.87 billion by 2035.

The latest cell and gene therapy market report analyzes performance from 2020 to 2025 and provides forecasts through 2030 and 2035. It evaluates major market segments, regional developments, leading economies, competitive activity, emerging technologies and strategic opportunities for companies operating across the global industry.

Historic market growth was supported by the shift toward personalized and precision medicine, the expansion of clinical trials, strong therapeutic pipelines, rising healthcare expenditure and increased investment in pharmaceutical and biotechnology companies. High treatment and development costs, combined with limited healthcare access in some markets, constrained wider adoption.

Future growth is expected to be driven by an aging global population, the rising prevalence of cancer, the increasing burden of chronic and genetic diseases, and continued investment in cell and gene therapy research, manufacturing and commercialization. Potential barriers include shortages of skilled professionals, stringent regulatory requirements, trade disruption and tariffs.

By product, cell therapy represented the largest segment in 2025, accounting for 69% of the market, or $10.99 billion. Cell therapy is also expected to generate the largest increase in annual sales by 2030, adding $17.48 billion. Gene therapy, however, is forecast to be the fastest-growing product segment between 2025 and 2030, with a CAGR of 26.1%.

Oncology remained the leading application, generating $8.69 billion and representing 54.6% of the global cell and gene therapy market in 2025. It is forecast to grow at a CAGR of 24.4% through 2030 and add $17.21 billion in annual sales. These projections position oncology as a central focus for therapeutic development, commercialization and investment.

Hospitals accounted for 60.3% of the market in 2025, equivalent to $9.61 billion, and are expected to capture an additional $17.15 billion in annual sales by 2030. Cancer care centers are forecast to be the fastest-growing end-user segment, expanding at a CAGR of 25% during the same period.

North America led the global market in 2025 with a 47.5% share, valued at $7.57 billion, followed by Western Europe and Asia-Pacific. Asia-Pacific is forecast to be the fastest-growing region through 2030, recording a CAGR of 27.5%. North America is expected to grow at 21.8%, followed by Eastern Europe at 21.4% and Africa at 21.3%. The United States offers the largest country-level opportunity, with projected market gains of $11.67 billion.

The cell and gene therapy market remains highly concentrated, with the 10 largest competitors accounting for 66.6% of the market in 2024. Gilead Sciences led with a 15.3% share, followed by Novartis AG at 12.8%, Bristol-Myers Squibb at 8.9%, Johnson & Johnson at 7.5%, Sarepta Therapeutics at 6.4% and Vertex Pharmaceuticals at 6.1%. Other prominent participants included CSL Limited, Krystal Biotech, F. Hoffmann-La Roche through Spark Therapeutics, and Amgen.

Key cell and gene therapy market trends include the commercialization of clinically validated allogeneic cell therapies, expansion of GMP-grade gene-editing platforms, development of scalable manufacturing infrastructure and increased localization of personalized CAR-T production. Companies are also investing in automated manufacturing for personalized induced pluripotent stem cell therapies, autologous T-cell immunotherapies, in-house production capacity and platform-agnostic integration systems.

Strategic partnerships are expected to play an increasingly important role in production, licensing, distribution and market access. Companies positioned to capitalize on growth will prioritize scalable allogeneic therapies, regulatory-ready gene-editing platforms, localized CAR-T manufacturing, accelerated oncology programs and collaboration-led distribution networks. Value-based pricing, access-focused communication and science-led stakeholder engagement will also be critical to supporting adoption and long-term commercial growth.

Executive Summary:

Cell and Gene Therapy Global Market Opportunities and Strategies to 2035 provides the strategists; marketers and senior management with the critical information they need to assess the global cell and gene therapy market as it emerges from the COVID-19 shut down.

Reasons to Purchase

The report covers the following chapters

Markets Covered:

1) By Product: Cell Therapy; Gene Therapy

2) By Application: Oncology; Neurological Disorders; Other Applications

3) By End User: Hospitals; Ambulatory Surgical Centers; Cancer Care Centers; Wound Care Centers; Other End Users

Companies Mentioned: Gilead Sciences.; Novartis AG; Bristol-Myers Squibb Company; Johnson & Johnson; Sarepta Therapeutics

Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; cell and gene therapy indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Key Attributes:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/n8y0gq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment